An IIT Clinical Study to Evaluate the Efficacy and Safety of IMC-001 for Injection on Improved Atherosclerotic Plaque Stability in Patients Receiving Optimal Medical Therapy Following a Recent Acute Coronary Syndrome (ACS)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs IMC 001 Suzhou Immunofoco Biotechnology (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Sponsors ImmuneOnco Biopharma
- 03 Feb 2025 New trial record